NextCure, Inc. (NXTC) Stock
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About NextCure, Inc.
NextCure, Inc. is led by CEO Michael S. Richman, employs 43 people, headquartered in US, publicly traded since 2019.
NextCure, Inc. (NXTC) stock trades at $4.98 with a market capitalization of $22.80M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.48, reflecting a net loss over the last twelve months, price-to-book of 2.24, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.55 and $15.74, and currently trades 68.4% below its 52-week high.
On profitability, NextCure, Inc. generates a return on equity (ROE) of -175.46% (negative, reflecting a net loss), return on capital employed of -270.88%.
NextCure, Inc. by the numbers, 2017–2025
Between 2017 and 2025 NextCure, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-56.0M.
On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-43.0M.
Borrowings rose from $1.0M to $5.0M, cash from operations was $-50.0M in the latest year, positive in 1 of the last 9.
Return on equity has averaged -75.1% over five years, and was -160.0% in the most recent year.
The share price itself has compounded at -53.3% a year over five years, -51.8% over three, -73.1% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
NextCure, Inc. (NXTC) — frequently asked questions
What is NextCure, Inc. (NXTC) stock price today?
NextCure, Inc. (NXTC) is currently trading at $4.98, up 5.51% today.
What is NXTC P/E ratio?
NextCure, Inc.'s P/E ratio is -0.48. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is NXTC return on equity (ROE)?
NextCure, Inc.'s return on equity (ROE) is -175.46%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is NextCure, Inc.'s market cap?
NextCure, Inc. has a market capitalization of $22.80M.
Does NXTC pay a dividend?
NextCure, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does NXTC carry?
NextCure, Inc. has a debt-to-equity ratio of 0.35. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is NXTC's profit margin?
NextCure, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is NXTC in?
NextCure, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is NXTC listed on?
NextCure, Inc. trades on NASDAQ under the ticker NXTC.
What is NXTC's 52-week range?
Over the last year NextCure, Inc. has traded between $1.55 and $15.74.
Related Healthcare Stocks
Popular Stocks
Screens NXTC currently matches
On the figures above, NextCure, Inc. passes the filters for 3 of our ready-made screens, among them Day Gainers Stocks, Penny Stocks, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.